loader image
Sunday, November 30, 2025
60.6 F
McAllen
- Advertisement -

How effective is the RSV vaccine during pregnancy and how does it work?

Translate to Spanish or other 102 languages!

How safe and effective is the RSV vaccine during pregnancy? Image for illustration purposes
How safe and effective is the RSV vaccine during pregnancy? Image for illustration purposes
- Advertisement -
  • RSV is a respiratory virus affecting about 64 million people around the world each year. 
  • While RSV symptoms may only feel like a common cold to adults and older children, it can be much more serious in older adults, babies, and young children. 
  • About 1.4 million children ages 0 to 6 months are hospitalized from RSV each year.
  • The CDC and American College of Obstetricians and Gynecologists both recommend pregnant people receive an RSV vaccine to help immunize their babies from the disease before they are born. 

Respiratory syncytial virus (RSV) is a respiratory virus causing infection in the lungs, nose, and throat.

Follow the link below to Medical News Today to read the full Story: 

https://www.medicalnewstoday.com/articles/how-safe-effective-is-rsv-vaccine-during-pregnancy

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral Hosting Webinar on Seasonal Depression, Dec. 4

Mega Doctor News It’s common for individuals to experience an emotional downturn during the winter...

AMA Adopts New Public Health Policies to Improve Health of the Nation

The American Medical Association (AMA) gathered physician and medical student leaders from all corners of medicine at its Interim Meeting of the House of Delegates to shape guiding policies on emerging health care topics.

Study Finds Best Strategy for Reducing Belly Fat

Over the last few years, research has shown that having excessive visceral fat — the fat surrounding the abdominal area that protects internal organs — can be detrimental to a person’s health.

FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy

The U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene. Itvisma is an adeno-associated virus (AAV) vector-based gene therapy.
- Advertisement -
×